J&J: Icotrokinra data shows durability in plaque psoriasis

Johnson & Johnson announced new data for Icotrokinra (icotrokinra) in difficult-to-treat plaque psoriasis, demonstrating durability through two years and affirming its use as a first-line systemic therapy.